Navigation Links
Abbott's Genetic Test for Acute Myeloid Leukemia Prognosis Cleared by FDA
Date:10/24/2011

DES PLAINES, Ill., Oct. 24, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has received 510(k) clearance from the U.S. Food and Drug Administration for a new in vitro diagnostic test to aid in determining the prognosis of patients with acute myeloid leukemia (AML), one of the most common types of leukemia in older adults.

Abbott's Vysis EGR1 FISH Probe Kit, the third Abbott FISH assay approved or cleared in the past two months by the FDA for oncology applications, detects a chromosomal deletion in bone marrow that is usually associated with an unfavorable prognosis for AML patients.  In AML, fast-growing abnormal white blood cells in bone marrow replace healthy cells and impede the body's ability to fight infection.  Eventually, the bone marrow ceases to function properly, leaving patients infection-prone and at risk for bleeding.  More than 12,000 people are diagnosed with AML each year. Because acute leukemia may rapidly progress, most AML patients are treated aggressively with chemotherapy drugs. Some patients may require a stem-cell transplant to replace unhealthy bone marrow with leukemia-free stem cells.  

"Abbott's Vysis EGR1 FISH Probe Kit can identify which AML patients have the chromosomal abnormality upon diagnosis and provides physicians with another clinically validated tool to assess a patient's overall prognosis," said Stafford O'Kelly, head of Abbott's molecular diagnostics business.

Published reports from several large clinical studies and the National Comprehensive Cancer Network guidelines suggest that chromosomal abnormalities associated with AML are valuable prognostic indicators. One study, conducted as part of an Eastern Cooperative Oncology Group (ECOG) clinical trial, demonstrated the utility of FISH technology to separate AML patients into risk categories based on chromosomal status or changes. Based on these categories, physicians are able to establish an effective disease management approach.

Technical Information on the EGR1 FISH Assay

The Vysis EGR1 FISH Probe Kit is intended to detect deletion of LSI EGR1 probe target on chromosome 5q in bone marrow specimens and may be used, in addition to cytogenetics, other biomarkers, morphology and other clinical information, at the time of acute myeloid leukemia (AML) diagnosis as an aid in determining prognosis. Deletion of chromosome 5q has been associated with an unfavorable prognosis in AML patients.

About FISH

FISH (fluorescence in-situ hybridization) technology has a variety of uses.  It can identify whether too many, or too few, copies of a particular gene are present in the body's cells or whether certain genes have rearrangements that play an active role in disease progression. Cancer diagnostics is one of the fastest growing applications.

The Vysis EGR1 FISH Probe Kit is the latest addition to Abbott Molecular's growing list of FISH-based in vitro diagnostic products available in the U.S. In August, the agency cleared Abbott's Vysis CLL FISH Probe Kit and approved the Abbott Vysis ALK Break Apart FISH Probe Kit.  Abbott also offers FISH-based tests for breast and bladder cancer.

About Abbott Molecular

Abbott Molecular, abbottmolecular.com, is a leader in molecular diagnostics — the analysis of DNA and RNA at the molecular level. Abbott Molecular's tests can also detect subtle but key changes in patients' genes and chromosomes and have the potential for earlier detection or diagnosis, provide information relevant to the selection of appropriate therapies, and may improve monitoring of disease progression.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs nearly 90,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novel New Dog DNA Test Turns Breeders Into Genetic Matchmakers
2. Genetic Profile Identified for Alzheimers Patients Showing Heightened Response to Acceras Breakthrough Product Axona®
3. Good Start Genetics to Announce Validation Study Results for its Next-Generation DNA Sequencing Platform During an Oral Presentation at the 2011 Annual Meeting of the American Society for Reproductive Medicine (ASRM)
4. American College of Medical Genetics Applauds HHS Secretarys Decision to Expand Newborn Screening to Include Critical Congenital Heart Disease
5. Ambry Genetics Announces Launch of Their CancerArray™ Product and Services Utilizing aCGH Technology
6. The Leukemia & Lymphoma Society Available to Comment on FDA Approval of Seattle Genetics Adcetris, First New Treatment for Hodgkin Lymphoma Since 1977
7. Genetic Testing Can Help the US Cut Costs and Improve Health Care
8. Metamark Genetics Announces Cancer Cell Study Highlighting Discovery of Key Molecules that Drive Progression of Malignant Melanoma in Humans
9. Metamark Genetics Partners with Definiens on Tissue-Based Cancer Diagnostics
10. Signal Genetics and DiagnoCure Announce a US$13.3M Collaboration for the Commercialization of Previstage™ GCC Colorectal Cancer Staging Test
11. Research 2.0 Updates Coverage of Viral Genetics with Research Report Focused on VG Energy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
(Date:4/19/2017)... -- The Global Effective Microorganisms (EM) Market by ... covered and analysed the potential of Global Effective Microorganisms (EM) ... and growth factors. The report identifies and analyses the emerging ... global market. ... Tables and Figures, 6 Major Company Profiles, spread across 124 ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s Home ... University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. , ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... tubes . These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps ... fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ...
(Date:4/28/2017)... ... ... The Texas Cord Blood Bank (TCBB), a program of nonprofit biomedical organization GenCure, ... at Renaissance in Edinburg for their outstanding efforts in collecting umbilical cord blood donations ... , “Women’s Hospital at Renaissance has been a collection partner for the TCBB since ...
(Date:4/28/2017)... Ca (PRWEB) , ... April 28, 2017 , ... Bill ... management industry in the coastal communities. After Tina Howe joined the team, the Bill ... happy employees, honest services at affordable rates, and giving back to the San Diego ...
Breaking Medicine News(10 mins):